Announcement on Voluntary Disclosure of Positive Preliminary Results of the Phase Ib Clinical Study of the Innovative Drug SGC001 of the Joint-stock Company

About this update from Beijing Hotgen Biotech Co. Ltd. Class A

Announcement on Voluntary Disclosure of Positive Preliminary Results of the Phase Ib Clinical Study of the Innovative Drug SGC001 of the Joint-stock CompanyThe abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Beijing Hotgen Biotech Co. Ltd. Class A